A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2012
At a glance
- Drugs Egaptivon pegol (Primary)
- Indications Embolism and thrombosis; Von Willebrand disease
- Focus Pharmacodynamics
- 24 Mar 2012 Planned number of patients changed from 2 to 3 and additional trial location (Austria) added as reported by European Clinical Trials Database.
- 02 Sep 2009 New trial record